Rankings
▼
Calendar
CRBU
Caribou Biosciences, Inc.
$186M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-41.6% YoY
Gross Profit
-$28M
-1337.8% margin
Operating Income
-$39M
-1871.7% margin
Net Income
-$35M
-1708.7% margin
EPS (Diluted)
$-0.39
QoQ Revenue Growth
+2.6%
Cash Flow
Operating Cash Flow
-$35M
Free Cash Flow
-$36M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$313M
Total Liabilities
$60M
Stockholders' Equity
$253M
Cash & Equivalents
$16M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$4M
-41.6%
Gross Profit
-$28M
$2M
-1854.2%
Operating Income
-$39M
-$37M
-3.8%
Net Income
-$35M
-$35M
-2.9%
Geographic Segments
UNITED STATES
$5M
96%
Non-US
$197,000
4%
← FY 2024
All Quarters
Q1 2025 →
CRBU Q4 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena